Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $23.00 price target on the stock.

Several other research firms also recently commented on TARA. Piper Sandler started coverage on Protara Therapeutics in a report on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Protara Therapeutics Stock Performance

Shares of TARA opened at $6.53 on Tuesday. The stock has a market cap of $337.14 million, a PE ratio of -4.57 and a beta of 1.38. Protara Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The firm’s 50-day simple moving average is $5.82 and its two-hundred day simple moving average is $4.93.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Monday, November 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. Equities research analysts predict that Protara Therapeutics will post -3.32 EPS for the current year.

Hedge Funds Weigh In On Protara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in Protara Therapeutics by 8.2% in the third quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock valued at $148,000 after acquiring an additional 2,596 shares during the period. Two Sigma Investments LP lifted its holdings in Protara Therapeutics by 35.8% during the third quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock valued at $85,000 after purchasing an additional 5,154 shares in the last quarter. Bailard Inc. increased its stake in Protara Therapeutics by 23.2% in the 3rd quarter. Bailard Inc. now owns 36,669 shares of the company’s stock worth $160,000 after buying an additional 6,900 shares in the last quarter. GSA Capital Partners LLP raised its stake in Protara Therapeutics by 9.0% during the 3rd quarter. GSA Capital Partners LLP now owns 101,488 shares of the company’s stock valued at $441,000 after purchasing an additional 8,375 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Protara Therapeutics in the second quarter worth $30,000. Institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.